Treatment Options for Severe Obesity in the Pediatric Population: Current Limitations and Future Opportunities
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Objective: Severe obesity is the only obesity classification increasing in prevalence among children and adolescents. Treatment options that produce meaningful and sustained weight loss and comorbidity resolution are urgently needed. Methods: The purpose of this review is to provide a brief overview of the current treatment options for pediatric severe obesity and offer suggestions regarding future opportunities for accelerating the development and evaluation of innovative treatment strategies. Results: At present, there are three treatment options for youth with severe obesity: lifestyle modification therapy, pharmacotherapy, and bariatric surgery. Lifestyle modification therapy can be useful for improving many chronic disease risk factors and comorbid conditions but often fails to achieve clinically meaningful and sustainable weight loss. Pharmacotherapy holds promise as an effective adjunctive treatment but remains in the primordial stages of development in the pediatric population. Bariatric surgery provides robust weight loss and risk factor/comorbidity improvements but is accompanied by higher risks and lower uptake compared to lifestyle modification therapy and pharmacotherapy. New areas worth pursuing include combination pharmacotherapy, device therapy, identification of predictors of response aimed at precision treatment, and interventions in the postbariatric surgical setting to improve long‐term outcomes. Conclusions: Treating pediatric severe obesity effectively and safely is extremely challenging. Some progress has been made, but substantially more effort and innovation are needed in the future to combat this serious and ongoing medical and public health issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Childhood and Adult Obesity in the United States, 2011-2012
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014) · JAMA · doi:10.1001/jama.2014.732 · Cited by 8,072
Childhood Adiposity, Adult Adiposity, and Cardiovascular Risk Factors
Juonala, M., Magnussen, C. G., Berenson, G. S., Venn, A., Burns, T. L., Sabin, M. A., Srinivasan, S. R., Daniels, S. R., Davis, P. H., Chen, W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010112 · Cited by 1,665
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood
Twig, G., Yaniv, G., Levine, H., Leiba, A., Goldberger, N., Derazne, E., Ben-Ami Shor, D., Tzur, D., Afek, A., Shamiss, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1503840 · Cited by 1,003 · cited 9×
“Importantly, glycosuria has been observed even in adults without diabetes under both fasting and postprandial conditions, and while the rates of glycosuria are lower in the context of normal glucose tolerance versus T2D, the relative amounts of glucose wasting under both fasting and postprandial conditions are still h…”
BackgroundInfluentialKelly, A. S., Barlow, S. E., Rao, G., Inge, T. H., Hayman, L. L., Steinberger, J., Urbina, E. M., Ewing, L. J., & Daniels, S. R. (2013) · Circulation · doi:10.1161/cir.0b013e3182a5cfb3 · Cited by 980 · cited 3×
“However, because obesity often is Obesity Future Treatments for Pediatric Severe Obesity Ryder et al. 956 Obesity | VOLUME 26 | NUMBER 6 | JUNE 2018 www.obesityjournal.org accompanied by comorbidities or risk for other serious chronic diseases (e.g., CVD, NAFLD, T2D) (10), evaluation of how obesity treatments impact c…”
BackgroundSelf-citationLong-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Weight loss and health status 3 years after bariatric surgery in adolescents
Inge, T. H., Courcoulas, A. P., Jenkins, T. M., Michalsky, M. P., Helmrath, M. A., Brandt, M. L., Harmon, C. M., Zeller, M. H., Chen, M. K., Xanthakos, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506699 · Cited by 750 · cited 4×
“Of note, bariatric surgery appears to produce meaningful benefits in terms of glycemic control along with potentially impressive remission rates (51,97,98).”
BackgroundInfluentialA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Caleyachetty, R., Thomas, G. N., Toulis, K. A., Mohammed, N., Gokhale, K. M., Balachandran, K., & Nirantharakumar, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.763 · Cited by 574 · cited 2×
“, reducing heterogeneity of response), and (3) improving reimbursement from insurance companies to increase access for youth who meet medical eligibility guidelines.”
BackgroundPhysiological adaptations to weight loss and factors favouring weight regain
Greenway, F. L. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.59 · Cited by 431 · cited 1×
“Further, the desire for and sensory response to food increase and, finally, total and resting energy expenditure diminish due to decreased body mass and enhanced metabolic efficiency (42).”
BackgroundCentral and Peripheral Regulation of Food Intake and Physical Activity: Pathways and Genes
Lenard, N. R., & Berthoud, H. (2008) · Obesity · doi:10.1038/oby.2008.511 · Cited by 338
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Collet, T.-H., Dubern, B., Mokrosinski, J., Connors, H., Keogh, J. M., Mendes de Oliveira, E., Henning, E., Poitou-Bernert, C., Oppert, J.-M., Tounian, P., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.015 · Cited by 302
Inge, T. H., Jenkins, T. M., Xanthakos, S. A., Dixon, J. B., Daniels, S. R., Zeller, M. H., & Helmrath, M. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30315-1 · Cited by 298
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293 · cited 1×
“Importantly, glycosuria has been observed even in adults without diabetes under both fasting and postprandial conditions, and while the rates of glycosuria are lower in the context of normal glucose tolerance versus T2D, the relative amounts of glucose wasting under both fasting and postprandial conditions are still h…”
BackgroundAlmirall, D., Compton, S. N., Gunlicks‐Stoessel, M., Duan, N., & Murphy, S. A. (2012) · Statistics in Medicine · doi:10.1002/sim.4512 · Cited by 223 · cited 1×
“A SMART includes multiple intervention stages, and each stage corresponds to one of the decision points in the ultimate adaptive intervention (101).”
BackgroundIkramuddin, S., Blackstone, R. P., Brancatisano, A., Toouli, J., Shah, S. N., Wolfe, B. M., Fujioka, K., Maher, J. W., Swain, J., Que, F. G., et al. (2014) · JAMA · doi:10.1001/jama.2014.10540 · Cited by 214
Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children
Yanovski, J. A., Krakoff, J., Salaita, C. G., McDuffie, J. R., Kozlosky, M., Sebring, N. G., Reynolds, J. C., Brady, S. M., & Calis, K. A. (2011) · Diabetes · doi:10.2337/db10-1185 · Cited by 193 · cited 1×
“, phentermine, topiramate, metformin, orlistat, and GLP-1 receptor agonists [GLP-1RAs]), some of which are US Food and Drug Administration (FDA)–approved for the treatment of obesity in adults, have been investigated in the context of pediatric obesity (46-50).”
BackgroundComparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents
Inge, T. H., Laffel, L. M., Jenkins, T. M., Marcus, M. D., Leibel, N. I., Brandt, M. L., Haymond, M., Urbina, E. M., Dolan, L. M., Zeitler, P. S., et al. (2018) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.5763 · Cited by 189 · cited 1×
“Of note, bariatric surgery appears to produce meaningful benefits in terms of glycemic control along with potentially impressive remission rates (51,97,98).”
BackgroundGuidelines (2013) for managing overweight and obesity in adults
(2014) · Obesity · doi:10.1002/oby.20818 · Cited by 172
The EMPOWER Study Group, Sarr, M. G., Billington, C. J., Brancatisano, R., Brancatisano, A., Toouli, J., Kow, L., Nguyen, N. T., Blackstone, R., Maher, J. W., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0751-8 · Cited by 162 · cited 1×
“In a randomized controlled trial (2:1 treatment/control) of 294 adults with obesity, vagal blockade for 1 year failed to achieve greater weight loss (17% excess weight loss) than the control condition (16% excess weight loss), which consisted of an implanted device that was not fully activated (75).”
BackgroundHigh Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery
Xanthakos, S. A., Jenkins, T. M., Kleiner, D. E., Boyce, T. W., Mourya, R., Karns, R., Brandt, M. L., Harmon, C. M., Helmrath, M. A., Michalsky, M. P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.039 · Cited by 151 · cited 2×
“NAFLD commonly occurs in concert with obesity, with prevalence estimates ranging from 60% to 80% among youth with severe obesity (15,94).”
BackgroundTwo-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial
Apovian, C. M., Shah, S. N., Wolfe, B. M., Ikramuddin, S., Miller, C. J., Tweden, K. S., Billington, C. J., & Shikora, S. A. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2325-7 · Cited by 145 · cited 1×
“A 2-year longitudinal follow-up in those initially randomly assigned to vagal blockade (open-label extension) reported mean weight loss of approximately 8% for those continuing treatment (77).”
BackgroundPhentermine/Topiramate for the Treatment of Obesity
Smith, S. M., Meyer, M., & Trinkley, K. E. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r501 · Cited by 122 · cited 1×
“The most effective current pharmacotherapy treatment for obesity in adults is the combination phentermine/topiramate with weight loss ranging from 7% (mid-dose) to 9% (high-dose) (67).”
BackgroundHollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017) · Diabetes Care · doi:10.2337/dc16-2427 · Cited by 106
Cardiovascular effects of bariatric surgery
Beamish, A. J., Olbers, T., Kelly, A. S., & Inge, T. H. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.162 · Cited by 84
Self-citationSchwartz, J., Suzo, A., Wehr, A. M., Foreman, K. S., Mikami, D. J., Needleman, B. J., & Noria, S. F. (2016) · Obesity Surgery · doi:10.1007/s11695-015-1979-x · Cited by 84
Precision medicine in adult and pediatric obesity: a clinical perspective
Bomberg, E. M., Ryder, J. R., Brundage, R. C., Straka, R. J., Fox, C. K., Gross, A. C., Oberle, M. M., Bramante, C. T., Sibley, S. D., & Kelly, A. S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863022 · Cited by 52
Self-citation
Cited by
Martínez-Lozano, N., Tvarijonaviciute, A., Ríos, R., Barón, I., Scheer, F. A. J. L., & Garaulet, M. (2020) · Nutrients · doi:10.3390/nu12092881 · Cited by 66
“Nevertheless, successful treatments of obesity in children remain a challenge [2] and underlying causes should be investigated more deeply, in order to improve the prevention of obesity at these ages.”
BackgroundCurrent and future pharmacotherapies for obesity in children and adolescents
Kelly, A. S. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00858-9 · Cited by 54
Self-citationPrecision medicine in adult and pediatric obesity: a clinical perspective
Bomberg, E. M., Ryder, J. R., Brundage, R. C., Straka, R. J., Fox, C. K., Gross, A. C., Oberle, M. M., Bramante, C. T., Sibley, S. D., & Kelly, A. S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863022 · Cited by 52
Self-citation
Metadata
- Authors
- Ryder, J. R., Fox, C. K., & Kelly, A. S.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2018-05-07
- Volume
- 26
- Issue
- 6
- Pages
- 951-960
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2801344176
- Cited by
- 83
- References
- 27
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.